Clinical predictors of survival in idiopathic pulmonary fibrosis

Tuberculosis and Respiratory Diseases

Volumn 73, Issue 3, 2012, Pages 162-168

  Kim, Ji Hye ^a   Lee, Jin Hwa ^a   Ryu, Yon Ju ^a   Chang, Jung Hyun ^a  

^a Ewha Womans University School of Medicine   (South Korea)

Author keywords

Body mass index; Disease progression; Idiopathic pulmonary fibrosis

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PROGNOSIS; SURVIVAL TIME;

EID: 84868270510     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2012.73.3.162     Document Type: Article

References (39)

1. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304.
2. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
3. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: 1107-36.
4. Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006;3:285-92. (Pubitemid 43845404)
5. Nagai S, Nagao T, Kitaichi M, Izumi T. Clinical courses of asymptomatic cases with idiopathic pulmonary fibrosis and a histology of usual interstitial pneumonia. Eur Respir J 1998;11:131s.
6. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157:199-203. (Pubitemid 28071283)
7. Nagai S, Kitaichi M, Hamada K, Nagao T, Hoshino Y, Miki H, et al. Hospital-based historical cohort study of 234 histologically proven Japanese patients with IPF. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:209-14. (Pubitemid 29469102)
8. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-42. (Pubitemid 37088595)
9. Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:543-8. (Pubitemid 37088596)
10. Jegal Y, Kim DS, Shim TS, Lim CM, Lee SD, Koh Y, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005:171:639-44. (Pubitemid 40365421)
11. Nicholson AG, Colby TV, Dubois RM, Hansell DM, Wells AU. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000;162:2213-7. (Pubitemid 32051689)
12. Travis WD, Matsui K, Moss J, Ferrans VJ. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol 2000;24:19-33. (Pubitemid 30033393)
13. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125-33. (Pubitemid 38056223)
14. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-42. (Pubitemid 41697286)
15. Scientific Committee of the Korean Academy of Tuberculosis and Respiratory Diseases. 2008 National Survey of Idiopathic Interstitial Pneumonia in Korea. Tuberc Respir Dis 2009;66:141-51.
16. Panos RJ, Mortenson RL, Niccoli SA, King TE Jr. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990;88:396-404. (Pubitemid 20147276)
17. Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 1993;103:1808-12. (Pubitemid 23174318)
18. Ambrosini V, Cancellieri A, Chilosi M, Zompatori M, Trisolini R, Saragoni L, et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J 2003;22:821-6. (Pubitemid 37369573)
19. Akira M, Hamada H, Sakatani M, Kobayashi C, Nishioka M, Yamamoto S. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. AJR Am J Roentgenol 1997;168:79-83. (Pubitemid 27014751)
20. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040-7. (Pubitemid 40616955)
21. Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006;27:143-50. (Pubitemid 43092678)
22. Parambil JG, Myers JL, Ryu JH. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest 2005;128:3310-5. (Pubitemid 41698656)
23. Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005;128:1475-82. (Pubitemid 41324435)
24. Kondoh Y, Taniguchi H, Yokoi T, Nishiyama O, Ohishi T, Kato T, et al. Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia. Eur Respir J 2005;25:528-33. (Pubitemid 40331185)
25. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005;142(12 Pt 1):963-7.
26. King TE Jr, Schwarz MI, Brown K, Tooze JA, Colby TV, Waldron JA Jr, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001;164:1025-32. (Pubitemid 32971653)
27. Flaherty KR, Colby TV, Travis WD, Toews GB, Mumford J, Murray S, et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med 2003;167:1410-5. (Pubitemid 36609727)
28. Nicholson AG, Fulford LG, Colby TV, du Bois RM, Hansell DM, Wells AU. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002;166:173-7. (Pubitemid 34765453)
29. World Health Organization. Obesity: preventing and managing the global epidemic. Report on a WHO Consultation. WHO Technical Report Series No. 894. Geneva: World Health Organization; 2000.
30. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006;173:1390-413. (Pubitemid 43900715)
31. Stark LJ, Powers SW. Behavioral aspects of nutrition in children with cystic fibrosis. Curr Opin Pulm Med 2005;11:539-42. (Pubitemid 41565006)
32. Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med 2006;173:475-82.
33. Cano NJ, Pichard C, Roth H, Court-Fortuné I, Cynober L, Gérard-Boncompain M, et al. C-reactive protein and body mass index predict outcome in end-stage respiratory failure. Chest 2004;126:540-6. (Pubitemid 39093441)
34. Alakhras M, Decker PA, Nadrous HF, Collazo-Clavell M, Ryu JH. Body mass index and mortality in patients with idiopathic pulmonary fibrosis. Chest 2007;131:1448-53. (Pubitemid 46762351)
35. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-83. (Pubitemid 44453463)
36. Savino W. The thymus gland is a target in malnutrition. Eur J Clin Nutr 2002;56 Suppl 3:S46-9.
37. Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003;167:735-40. (Pubitemid 36801751)
38. Mejía M, Carrillo G, Rojas-Serrano J, Estrada A, Suárez T, Alonso D, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009;136:10-5.
39. Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005;26:586-93. (Pubitemid 41448654)